[go: up one dir, main page]

PL3246032T3 - Kompozycje farmaceutyczne z kwasem zoledronowym, wapniem i witaminą d, odpowiednie do leczenia i/lub profilaktyki chorób metabolicznych kości oraz działań ubocznych spowodowanych terapią, takich jak hipokalcemia - Google Patents

Kompozycje farmaceutyczne z kwasem zoledronowym, wapniem i witaminą d, odpowiednie do leczenia i/lub profilaktyki chorób metabolicznych kości oraz działań ubocznych spowodowanych terapią, takich jak hipokalcemia

Info

Publication number
PL3246032T3
PL3246032T3 PL17171880T PL17171880T PL3246032T3 PL 3246032 T3 PL3246032 T3 PL 3246032T3 PL 17171880 T PL17171880 T PL 17171880T PL 17171880 T PL17171880 T PL 17171880T PL 3246032 T3 PL3246032 T3 PL 3246032T3
Authority
PL
Poland
Prior art keywords
treatment
hypocalcaemia
prophylaxis
vitamin
calcium
Prior art date
Application number
PL17171880T
Other languages
English (en)
Inventor
Rüdiger THIEROLF
Christoph Karl
Original Assignee
Christoph Karl
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Christoph Karl filed Critical Christoph Karl
Publication of PL3246032T3 publication Critical patent/PL3246032T3/pl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/59—Compounds containing 9, 10- seco- cyclopenta[a]hydrophenanthrene ring systems
    • A61K31/593—9,10-Secocholestane derivatives, e.g. cholecalciferol, i.e. vitamin D3
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/06—Aluminium, calcium or magnesium; Compounds thereof, e.g. clay
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/02—Nutrients, e.g. vitamins, minerals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Epidemiology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Pain & Pain Management (AREA)
  • Nutrition Science (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Inorganic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
PL17171880T 2016-05-20 2017-05-19 Kompozycje farmaceutyczne z kwasem zoledronowym, wapniem i witaminą d, odpowiednie do leczenia i/lub profilaktyki chorób metabolicznych kości oraz działań ubocznych spowodowanych terapią, takich jak hipokalcemia PL3246032T3 (pl)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE102016006446 2016-05-20
EP17171880.2A EP3246032B1 (de) 2016-05-20 2017-05-19 Pharmazeutische zusammensetzungen mit zoledronsaeure, kalzium und vitamin d, geeignet zur behandlung und/oder prophylaxe von erkrankungen des knochenstoffwechsels und von therapiebedingten nebenwirkungen wie hypokalzaemien

Publications (1)

Publication Number Publication Date
PL3246032T3 true PL3246032T3 (pl) 2022-01-03

Family

ID=58800639

Family Applications (1)

Application Number Title Priority Date Filing Date
PL17171880T PL3246032T3 (pl) 2016-05-20 2017-05-19 Kompozycje farmaceutyczne z kwasem zoledronowym, wapniem i witaminą d, odpowiednie do leczenia i/lub profilaktyki chorób metabolicznych kości oraz działań ubocznych spowodowanych terapią, takich jak hipokalcemia

Country Status (6)

Country Link
EP (1) EP3246032B1 (pl)
DE (1) DE102017110957A1 (pl)
DK (1) DK3246032T3 (pl)
ES (1) ES2893753T3 (pl)
PL (1) PL3246032T3 (pl)
PT (1) PT3246032T (pl)

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2497353C (en) * 2002-09-16 2012-08-28 Novartis Ag Method for preventing or reducing secondary fractures after hip fracture
US20100144679A1 (en) * 2007-03-21 2010-06-10 Duke University Medication kits and formulations for preventing, treating or reducing secondary fractures after previous fracture
WO2016020508A2 (en) * 2014-08-07 2016-02-11 Opko Ireland Global Holdings Ltd. Adjunctive therapy with 25-hydroxyvitamin d

Also Published As

Publication number Publication date
EP3246032A1 (de) 2017-11-22
DE102017110957A1 (de) 2017-11-23
ES2893753T3 (es) 2022-02-10
PT3246032T (pt) 2021-10-18
EP3246032B1 (de) 2021-08-11
DK3246032T3 (da) 2021-10-11

Similar Documents

Publication Publication Date Title
MX2022009155A (es) Nuevos profarmacos polimericos de la hormona del crecimiento humana (hgh).
SG11202106160WA (en) Pharmaceutical composition for prevention or treatment of cancer comprising weissella cibaria wikim28 as active ingredient
PH12018502634A1 (en) Topical compositions of apremilast
EP3180009A4 (en) Zoledronic acid dosage forms for the treatment of pain
PH12014500558A1 (en) Composition for use in the promotion of healthy bone growth and/or in the prevention and/or treatment of bone disease
MX2015016497A (es) Composicion solida para administracion oral que contiene acido ibandronico o una sal farmaceuticamente aceptable del mismo y vitamina d.
MY176246A (en) Compositions for oral administration of zoledronic acid or related compounds for treating disease
MX2015010139A (es) Composicion antiseptica oral para tratamiento de mucositis oral.
IL251687A0 (en) Medicinal composition for use in treatment to prevent vitamin and mineral deficiencies in patients who have undergone gastric bypass surgery
MX2015012771A (es) Procedimiento de tratamiento de la deficiencia de vitamina b12.
ZA201906153B (en) Pharmaceutical compositions for combination therapy
PH12017500743B1 (en) Tau protein production accelerator, and therapeutic or preventive agent and therapeutic or preventive food composition for diseases caused by tau protein deficiency
GB2530226A (en) Chewable tablet
PT3246032T (pt) Composições farmacêuticas com ácido zoledrónico, cálcio e vitamina d adequadas para tratamento e/ou profilaxia de doenças do metabolismo ósseo e de efeitos secundários relacionados com terapia, como hipocalcemias
WO2019022602A8 (en) Pharmaceutical composition for use in the treatment or prevention of vitamin deficiency and mineral deficiency in patients who have been subjected to gastric sleeve surgery
MX350569B (es) Composicion farmaceutica estable para el tratamiento de osteoporosis.
EP3881845A3 (en) Combination of trazodone and gabapentin for the treatment of pain
IL257689B (en) Pharmaceutical preparations and methods for treating diseases related to lack of oxygen
MX2018004019A (es) Formulacion novedosa y metodos de tratamiento.
PH12017501693A1 (en) Compositions for the treatment of kidney and/or liver diseases
NZ739679A (en) Cholecalciferol sulfate salts and their use for the treatment of vitamin d deficiency
MX2016017336A (es) Uso de acido bisfosfonico y sus sales en la preparacion de composiciones utiles en el tratamiento de la osteoporosis.
ZA202104321B (en) Aqueous paediatric retinol formulations
IN2013MU03034A (pl)
WO2016092377A3 (ru) Композиция, содержащая глюкозамин, фруктобарат кальция и витамин d для лечения и/или профилактики нарушений, связанных с воспалительными заболеваниями суставов и позвоночника